Association between anti-Mullerian hormone and insulin resistance in non-obese adolescent females with polycystic ovary syndrome

References

• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013;6:1–13
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013;28:777–84
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann DA, Legro RS, et al. PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932–7
   PubMed Web of Science ®Google Scholar
• Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891–9
   PubMed Web of Science ®Google Scholar
• La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103–7
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83
   PubMed Web of Science ®Google Scholar
• Carmina E, Orio F, Palomba S, et al. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril 2005;84:413–19
   PubMed Web of Science ®Google Scholar
• La Marca A, Morgante G, Palumbo M, et al. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 2002;78:1234–9
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Witchel SF, Casper RF. Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 2002;9:163–7
   PubMedGoogle Scholar
• Piltonen T, Morin-Papunen L, Koivunen R, et al. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20:1820–6
   PubMed Web of Science ®Google Scholar
• Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012;27:14–24
   PubMed Web of Science ®Google Scholar
• Yin J, Li M, Xu L, et al. Insulin resistance determined by Homeostasis Model Assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers. Diabetol Metab Syndr 2013;5:71(e1–9)
   PubMed Web of Science ®Google Scholar
• Tresaco B, Bueno G, Pineda I, et al. Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005;61:381–8
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Lazzarini V, et al. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol 2009;25:335–43
   PubMed Web of Science ®Google Scholar
• Li L, Chen X, Mo Y, et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr 2010;122:519–24
   PubMed Web of Science ®Google Scholar
• Fonseca HP, Brondi RS, Piovesan FX, et al. Anti-Mullerian hormone and insulin resistance in polycystic ovary syndrome. Gynecol Endocrinol 2014;30:667–70
   PubMed Web of Science ®Google Scholar
• Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–23
   PubMed Web of Science ®Google Scholar
• La Marca A, Pati M, Orvieto R, et al. Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006;85:1547–9
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Margalioth EJ, Gal M, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20:1814–19
   PubMed Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–2
   PubMed Web of Science ®Google Scholar
• Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010;139:825–33
   PubMed Web of Science ®Google Scholar
• Tian X, Ruan X, Mueck AO, et al. Anti-Müllerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecol Endocrinol 2014;30:126–9
   PubMed Web of Science ®Google Scholar
• Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;23:952–7
   PubMed Web of Science ®Google Scholar
• Nardo LG, Yates AP, Roberts SA, et al. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009;24:2917–23
   PubMed Web of Science ®Google Scholar
• Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf) 2014;81:899–906
   PubMed Web of Science ®Google Scholar
• Caglar GS, Kahyaoglu I, Pabuccu R, et al. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 2013;288:905–10
   PubMed Web of Science ®Google Scholar
• Tian X, Ruan X, Mueck AO, et al. Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecol Endocrinol 2014;30:836–9
   PubMed Web of Science ®Google Scholar
• Crisosto N, Codner E, Maliqueo M, et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739–43
   PubMed Web of Science ®Google Scholar